Indirubin treatment reduces cell growth and enhances apoptosis and autophagy in cervical cancer, suggesting its therapeutic potential.
This study investigated the effects of indirubin on autophagy and apoptosis in cervical cancer models, with a focus on elucidating the underlying molecular mechanisms. A xenograft tumor model in BALB/c-Nude mice and in vitro experiments using HeLa cell lines were employed. Indirubin treatment demonstrated a concentration-dependent inhibition of cervical cancer cell growth, accompanied by the induction of apoptosis and autophagy. Mechanistic analysis revealed that these effects were associated with the modulation of the PI3K/AKT signaling axis. This was evidenced by enhanced autophagic flux, indicated by an increased LC3-II/LC3-I ratio and decreased P62 expression, and concurrent induction of mitochondrial apoptosis, marked by upregulated pro-apoptotic Bax and downregulated anti-apoptotic Bcl-2 levels. Furthermore, indirubin treatment was linked to the inhibition of the MEKK1/SEK1/JNK/AP-1 signaling pathway, which may also contribute to its anti-tumor effects. These findings suggest that the anti-tumor activity of indirubin is associated with the regulation of the PI3K/AKT and MAPK pathways, the enhancement of autophagy, and the promotion of apoptosis, providing a theoretical basis for its therapeutic potential in cervical cancer treatment.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: